Subtopic Deep Dive

Complement Factor H in Diseases
Research Guide

What is Complement Factor H in Diseases?

Complement Factor H (CFH) is a key regulator of the complement system whose polymorphisms and dysregulation contribute to diseases like age-related macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS).

CFH inhibits the alternative complement pathway by accelerating C3b decay and acting as a cofactor for factor I. Genetic variants, particularly in the HF1/CFH gene, increase AMD risk through impaired regulation (Klein et al., 2005; 4456 citations). Studies link these polymorphisms to drusen formation and endothelial damage in renal disorders.

Curated Papers

Key Challenges

Why It Matters

CFH variants drive AMD pathogenesis, the leading cause of blindness in the elderly, enabling genetic risk prediction (Klein et al., 2005; Edwards et al., 2005). In aHUS, CFH deficiencies cause uncontrolled complement activation leading to thrombotic microangiopathy and renal failure. Therapeutic targeting of CFH, including monoclonal antibodies, supports precision medicine approaches (Merle et al., 2015). Hageman et al. (2005) identified haplotypes predisposing to AMD, guiding clinical genotyping.

Key Research Challenges

CFH Structure-Function Mapping

Resolving how Y402H polymorphism alters CFH binding to C3b and heparan sulfate remains challenging due to complex domain interactions. Structural studies are limited by protein instability (Hageman et al., 2005). Advanced cryo-EM is needed for therapeutic design.

Distinguishing Disease-Specific Variants

Separating AMD-linked polymorphisms from aHUS mutations requires large cohort genotyping amid overlapping phenotypes. GWAS data show locus heterogeneity on 1q25-31 (Edwards et al., 2005; Klein et al., 2005). Functional assays lag behind genetic associations.

Therapeutic CFH Modulation Safety

Balancing complement inhibition to treat AMD without infection risk or over-suppression poses regulatory hurdles. Animal models reveal dose-dependent thrombosis (Merle et al., 2015). Clinical translation needs biomarkers for patient stratification.

Essential Papers

Complement Factor H Polymorphism in Age-Related Macular Degeneration

Robert J. Klein, Caroline J. Zeiss, Emily Y. Chew et al. · 2005 · Science · 4.5K citations

Age-related macular degeneration (AMD) is a major cause of blindness in the elderly. We report a genome-wide screen of 96 cases and 50 controls for polymorphisms associated with AMD. Among 116,204 ...

Complement Factor H Polymorphism and Age-Related Macular Degeneration

Albert O. Edwards, Robert Ritter, Kenneth J. Abel et al. · 2005 · Science · 2.4K citations

Age-related macular degeneration (AMD) is a common, late-onset, and complex trait with multiple risk factors. Concentrating on a region harboring a locus for AMD on 1q25-31, the ARMD1 locus, we tes...

A common haplotype in the complement regulatory gene factor H ( <i>HF1/CFH</i> ) predisposes individuals to age-related macular degeneration

Gregory S. Hageman, Don H. Anderson, Lincoln V. Johnson et al. · 2005 · Proceedings of the National Academy of Sciences · 1.9K citations

Age-related macular degeneration (AMD) is the most frequent cause of irreversible blindness in the elderly in developed countries. Our previous studies implicated activation of complement in the fo...

Complement System Part I â€“ Molecular Mechanisms of Activation and Regulation

Nicolas S. Merle, S. Church, Véronique Frémeaux‐Bacchi et al. · 2015 · Frontiers in Immunology · 1.5K citations

Complement is a complex innate immune surveillance system, playing a key role in defense against pathogens and in host homeostasis. The complement system is initiated by conformational changes in r...

Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration

Bert Gold, Joanna E. Merriam, Jana Zernant et al. · 2006 · Nature Genetics · 1.1K citations

Complement System Part II: Role in Immunity

Nicolas S. Merle, Rémi Noé, Lise Halbwachs‐Mecarelli et al. · 2015 · Frontiers in Immunology · 988 citations

International audience

The complement system

J. Vidya Sarma, Peter A. Ward · 2010 · Cell and Tissue Research · 952 citations

Reading Guide

Foundational Papers

Start with Klein et al. (2005, 4456 citations) for AMD GWAS discovery, Edwards et al. (2005, 2423 citations) for locus fine-mapping, Hageman et al. (2005, 1941 citations) for haplotype-drusen link—these establish genetic causality.

Recent Advances

Merle et al. (2015, Part I/II, 1480+988 citations) detail CFH mechanisms in regulation/immunity; Anderson et al. (2009, 720 citations) hypothesizes aging role.

Core Methods

GWAS SNP genotyping (Klein/Edwards), haplotype analysis (Hageman), complement activation assays (Merle), structural modeling of SCR domains.

How PapersFlow Helps You Research Complement Factor H in Diseases

Discover & Search

Research Agent uses searchPapers and citationGraph to map CFH-AMD literature from Klein et al. (2005, 4456 citations), revealing 2005 Science cluster with Edwards et al. (2005) and Hageman et al. (2005). exaSearch uncovers aHUS-specific variants; findSimilarPapers extends to BF/C2 interactions (Gold et al., 2006).

Analyze & Verify

Analysis Agent employs readPaperContent on Klein et al. (2005) to extract polymorphism odds ratios, verified via verifyResponse (CoVe) against raw GWAS data. runPythonAnalysis performs meta-analysis of citation-sorted papers with pandas for variant frequency stats. GRADE grading scores evidence strength for AMD risk (high) versus aHUS (moderate).

Synthesize & Write

Synthesis Agent detects gaps in CFH-aHUS therapeutics post-Merle et al. (2015), flags contradictions between AMD haplotypes (Hageman et al., 2005). Writing Agent uses latexEditText, latexSyncCitations for Klein/Edwards papers, and latexCompile for review manuscripts; exportMermaid diagrams CFH regulation pathways.

Use Cases

"Analyze CFH polymorphism effect sizes across AMD GWAS datasets"

Research Agent → searchPapers('CFH AMD GWAS') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on Klein/Edwards odds ratios) → CSV export of pooled HRs with confidence intervals.

"Draft LaTeX review on CFH in aHUS with citations"

Synthesis Agent → gap detection (therapeutics post-Merle 2015) → Writing Agent → latexEditText(structure) → latexSyncCitations(Hageman/Klein) → latexCompile(PDF with CFH pathway figure).

"Find GitHub code for CFH structural modeling"

Research Agent → paperExtractUrls(Merle 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect(AlphaFold CFH models) → runPythonAnalysis(visualize PDB variants).

Automated Workflows

Deep Research workflow scans 50+ CFH papers via citationGraph from Klein et al. (2005), generating structured reports on AMD vs. aHUS variants. DeepScan applies 7-step CoVe to verify polymorphism penetrance, checkpointing GRADE scores. Theorizer synthesizes CFH dysregulation hypothesis from 2005 trio (Klein/Edwards/Hageman), proposing testable mutants.

Try Doxa for Complement Factor H in Diseases Research

Frequently Asked Questions

What defines Complement Factor H's role in diseases?

CFH regulates alternative pathway by binding C3b and surfaces; Tyr402His variant impairs this, raising AMD risk 7-fold (Klein et al., 2005).

What methods study CFH polymorphisms?

Genome-wide SNP screens (116k loci) identified ARMD1 associations (Edwards et al., 2005); haplotypes via sequencing (Hageman et al., 2005).

What are key papers on CFH in AMD?

Klein et al. (2005, Science, 4456 citations) first reported Y402H; Edwards et al. (2005, 2423 citations) confirmed 1q31 locus; Hageman et al. (2005, 1941 citations) linked to drusen.